Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
34.29
-0.08 (-0.23%)
Feb 20, 2026, 4:00 PM EST - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $10.63M in the quarter ending September 30, 2025, with 117.25% growth. This brings the company's revenue in the last twelve months to $205.63M, up 1,128.17% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$205.63M
Revenue Growth
+1,128.17%
P/S Ratio
9.52
Revenue / Employee
$1,606,500
Employees
128
Market Cap
1.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Aurinia Pharmaceuticals | 265.81M |
| Vericel | 258.72M |
| Nektar Therapeutics | 62.60M |
| Nuvation Bio | 26.75M |
| Maze Therapeutics | 2.50M |
STOK News
- 2 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 9 days ago - Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
- 16 days ago - Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 24 days ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 5 weeks ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 5 weeks ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 6 weeks ago - Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire